Literature DB >> 16304162

Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata.

Francesco Barchiesi1, Elisabetta Spreghini, Serena Tomassetti, Daniela Arzeni, Daniele Giannini, Giorgio Scalise.   

Abstract

We investigated the fungicidal activity of caspofungin (CAS) and amphotericin B (AMB) against 16 clinical isolates of Candida glabrata. The minimum fungicidal concentrations (MFCs) of CAS were similar to those of AMB, ranging from 2.0 to >8.0 microg/ml. Time-kill assays performed on selected isolates showed that AMB was fungicidal at concentrations four times the MIC while CAS was not. A neutropenic-mouse model of disseminated infection was utilized to determine the residual fungal kidney burden. While doses as low as 0.3 and 1 mg/kg of body weight/day of CAS and AMB, respectively, were effective at reducing the counts with respect to controls, organ sterilization was reached when both drugs were administered at 5 mg/kg/day. Our study reveals that, similar to AMB, CAS has the potential for a fungicidal effect in vivo against this difficult-to-treat fungal pathogen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304162      PMCID: PMC1315975          DOI: 10.1128/AAC.49.12.4989-4992.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

5.  Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species.

Authors:  Emilia Cantón; Javier Pemán; Angel Viudes; Guillermo Quindós; Miguel Gobernado; Ana Espinel-Ingroff
Journal:  Diagn Microbiol Infect Dis       Date:  2003-03       Impact factor: 2.803

6.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

Review 7.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

8.  Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

Authors:  A L Colombo; J Perfect; M DiNubile; K Bartizal; M Motyl; P Hicks; R Lupinacci; C Sable; N Kartsonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-23       Impact factor: 3.267

9.  Caspofungin.

Authors:  Stanley C Deresinski; David A Stevens
Journal:  Clin Infect Dis       Date:  2003-05-19       Impact factor: 9.079

10.  Patterns of amphotericin B killing kinetics against seven Candida species.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Angel Viudes; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more
  12 in total

Review 1.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

2.  Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.

Authors:  Cornelius J Clancy; Hong Huang; Shaoji Cheng; Hartmut Derendorf; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.

Authors:  Yasemin Oz; Ilknur Dag; Nuri Kiraz
Journal:  Mycopathologia       Date:  2011-08-13       Impact factor: 2.574

Review 4.  Mechanisms of echinocandin antifungal drug resistance.

Authors:  David S Perlin
Journal:  Ann N Y Acad Sci       Date:  2015-07-17       Impact factor: 5.691

5.  Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species.

Authors:  Fernando C Bizerra; Analy S A Melo; Eduardo Katchburian; Edna Freymüller; Anita H Straus; Hélio K Takahashi; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-08       Impact factor: 5.191

6.  Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy.

Authors:  I D Jacobsen; S Brunke; K Seider; T Schwarzmüller; A Firon; C d'Enfért; K Kuchler; B Hube
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

7.  Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.

Authors:  Cristina Rueda; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

8.  In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection.

Authors:  Fabiola Fernández-Silva; Michaela Lackner; Javier Capilla; Emilio Mayayo; Deanna Sutton; Mariana Castanheira; Annette W Fothergill; Cornelia Lass-Flörl; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

9.  Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin.

Authors:  Jason M Cota; Jodi L Grabinski; Robert L Talbert; David S Burgess; P David Rogers; Thomas D Edlind; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

10.  Screening for drug-resistant Candida yeasts with chromogenic agar.

Authors:  William R Kirkpatrick; Joseph D Zimmerman; Fadi P Haikal; Michael J Broker; Erin Brockway; Annette W Fothergill; Dora I McCarthy; Thomas F Patterson; Spencer W Redding
Journal:  Med Mycol       Date:  2010-09       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.